More than a quarter of a century has elapsed since the identification of the c-src proto-oncogene. During that period, we have learned that cancer arises as the result of mutations in proto-oncogenes and tumor suppressor genes, and we are now seeing the first fruits of these discoveries, in the form of targeted therapies directed against activated tyrosine kinases such as Bcr-Abl, c-Kit and the EGF receptor. But the discovery of the c-src proto-oncogene was in turn based on decades of study on an avian RNA tumor virus, Rous sarcoma virus (RSV). Here I review the work that led up to the identification of the RSV transforming gene and its protein product, and how this information in turn led to the discovery of cellular Src.
In 1909 Peyton Rous, working at the Rockefeller Institute in New York, was given a barred Plymouth Rock hen bearing a large tumor, upon which microscopic examination appeared to be a spindle-cell sarcoma. The tumor proved to be transplantable to chickens of the same breed (Rous, 1910) , and in later passages to chickens of other breeds, and Rous named the tumor 'Chicken Tumor No. 1'. Surprisingly, cell-free filtrates could also transmit the disease, indicating that the tumor was due to a 'filterable agent', as viruses were then called (Rous, 1911) . Other chicken tumors with distinct pathologies, such as an osteochondrosarcoma that produced cartilage and bone, also proved to contain filterable agents. Peyton Rous was able to show that there were distinct agents, each of which produced tumors of the same type as the tumor from which it had been derived (Rous and Murphy, 1914) . In retrospect, this strain specificity was the first hint that the ability to induce tumors was a genetic property of the virus, although of course the idea that viruses could contain genetic information only emerged some 30 or 40 years later.
Even before Rous' discovery, Ellerman and Bang (1908) in Copenhagen had transmitted erythro-myeloblastic leukemias with cell-free filtrates. Fujinami and Inamoto (1914) , working independently of Rous at the Imperial University in Kyoto, Japan, isolated another transplantable chicken sarcoma, which a few years later they showed could also be transmitted by cell-free filtrates. However, the discoveries of these three groups were met with reactions ranging from indifference to skepticism and outright hostility. The prevailing attitude was that chicken leukemias and sarcomas must be unrelated to the human diseases, which are clearly noninfectious in origin, and thus could provide no useful information. Indeed, in one famous comment, frequently recounted by Rous himself, a British oncologist told him 'But, my dear fellow, don't you see, this can't be cancer because you know its cause' (Andrewes, 1971) . For many years, therefore, these discoveries were ignored. Fortunately, Rous lived long enough to see his ideas vindicated, and in 1966, at the age of 85, he received the Nobel Prize in Physiology or Medicine.
RSV strains and the induction of tumors in mammals
Thus, Rous sarcoma virus, as it was later to be called, remained outside the mainstream of cancer research for many decades. Nevertheless, the virus was distributed to many laboratories and information about the virus slowly accumulated. Progressively more potent variants of RSV were selected during the course of its travels. Early in its career in Rous' lab, the virus acquired the ability to induce tumors in other strains of chicken. Later passages proved to be tumorigenic in other avian hosts such as ducks and pigeons. Different strains were developed in different laboratories, among them the Carr-Zilber, Prague, Schmidt-Ruppin, Bryan, Harris and Mill-Hill strains; the history of these strains has been reviewed (Simons and Dougherty, 1963) . In the late 1950s, it was discovered that some of these strains could induce tumors in mammalian hosts such as rats, mice, hamsters and rabbits: in 1957 and 1958 two groups (both working independently in Moscow) reported that the Carr-Zilber strain could induce sarcomas in newborn rats (Svet-Moldavsky, 1957 , 1958 Kryukova, 1957, 1958) , and in 1959 Schmidt-Ruppin (1959) described similar results with both mice and rats. The ability of an avian tumor virus to induce tumors in mammals came as a great surprise; although by that time other tumor viruses had been discovered, and the idea that viruses could cause cancer was now accepted, tumor viruses were believed to induce tumors only in a few related species. As we shall see, the ability of certain strains of RSV to induce tumors in mammalian hosts later proved critical in the identification of the Src transforming protein.
The focus assay
It was the development of quantitative assays for RSV that opened the door to detailed studies on the biology of the virus. Keogh (1938) developed a method for quantifying infectious RSV, based on Rous and Murphy's early observation that small tumors or 'pocks' could be induced on the chorioallantoic membrane of the chicken embryo (Rous and Murphy, 1911) ; the assay involved counting the number of tumors formed on the chorioallantoic membrane by a diluted sample of the virus stock. In 1955, Harry Rubin used this assay to demonstrate that every cell in an RSV-induced tumor was capable of releasing virus. This implied that the virus was permanently associated with the host cell and could release infectious progeny without causing cell death. This in turn raised the possibility, as Rubin put it, that the virus 'plays a direct and continuing role in perpetuating the cell in its malignant state' (Rubin, 1955) .
Although the pock assay was useful for quantifying infectious RSV, it did not allow detailed studies on the interaction of the virus with the host cell. The focus assay, which was to prove crucial for subsequent work on RNA tumor viruses, was developed in Dulbecco's laboratory at Caltech. In the early 1950s, Dulbecco had been convinced by Max Delbru¨ck, one of the founders of molecular biology, that animal viruses could be studied by the same quantitative approaches that had been used to study the replication of bacteriophages. By 1953, Dulbecco and his collaborator Marguerite Vogt had developed a plaque assay for cytocidal (cell-killing) animal viruses (Dulbecco and Vogt, 1953) , but since RSV is not cytocidal the assay could not be used to quantify RSV. It had been reported in 1941 that chicken embryo fibroblasts (CEF) growing in culture became altered in appearance when infected with RSV, adopting the rounded or spindle-shaped morphology of Rous sarcoma cells (Halberstaedter et al., 1941) . Some 15 years later, Manaker and Groupe´(1956) found that when CEF were infected with RSV in a medium containing tryptose phosphate broth, transformed cells appeared in discrete foci, with the number of foci increasing in proportion to the dose of virus. However, since the infected cells were producing virus that could then reinfect other cells in the same dish, the number of foci did not represent an accurate estimate of the amount of infectious virus. Howard Temin, then a graduate student with Dulbecco, and Harry Rubin, a postdoctoral fellow, were able to develop a quantitative assay by overlaying the infected cells with nutrient agar, preventing released virus from diffusing away from the original foci (Temin and Rubin, 1958) . The focus assay revolutionized the study of RSV, making it possible to study the interaction of a single cell with a single-virus particle, and the development of this assay led to the rapid advances in retrovirology that began in the 1960s.
Replication-defective and nondefective strains
Peyton Rous and his successors in the field were puzzled by the finding that some tumors induced by RSV did not appear to produce detectable quantities of virus. In the 1950s, Ray Bryan at the National Cancer Institute carefully analysed this phenomenon, and discovered that tumors induced by low doses of virus often yielded no infectious virus, while tumors induced by higher doses generally did (Bryan et al., 1955) . With the development of the focus assay, it became possible to analyse the basis for transformation in the absence of virus production. Rubin (1960 Rubin ( , 1961 had discovered that many embryos contained an RSV-related virus termed RIF, or Rous interfering factor, which was nontransforming but interfered with infection by Rous sarcoma virus; this virus proved to be an avian leukosis virus, a common infection in domestic chickens, and the interference with RSV infection was subsequently shown to result from blockade of cell surface receptors required for viral penetration (Hanafusa, 1965) . Harry Rubin and Peter Vogt, then a postdoctoral fellow in the Rubin lab, went on to show that a similar non-transforming virus, which they called Rous-associated virus or RAV, was present in stocks of the Bryan high-titer strain of RSV (Rubin and Vogt, 1962) . Hidesaburo and Teruko Hanafusa, working in Rubin's lab, and, independently, Howard Temin, then discovered that when chicken embryo fibroblasts were infected with the Bryan hightiter strain at low multiplicities of infection (i.e. at high dilutions), transformed cells that did not release infectious virus could be isolated ('nonproducer' or NP cells) (Hanafusa et al., 1963; Temin, 1963) (Figure 1 ). When these 'nonproducer' cells were superinfected with the RAV, they released infectious RSV. Thus the Bryan strain of RSV was a replication-defective transforming virus that required a nontransforming helper virus (the RAV) for the production of infectious progeny ( Figure 1 ).
These findings on the Bryan strain of RSV suggested for the first time that virus replication and transformation could be dissociated. Indeed, it was argued at the time that the replication defect might actually be necessary for the ability to transform. Doubt was shed on this model when it was discovered that the so-called nonproducer cells actually produced noninfectious virus particles (Dougherty and Di Stefano, 1965; Vogt, 1967) . The hypothesis suffered a final blow when it was discovered that some strains of RSV, such as the Prague and Schmidt-Ruppin strains, were not replicationdefective (Golde´and Lacassagne, 1966) (Figure 1 ). It seems likely that the original isolate of RSV was replication-defective (Lerner and Hanafusa, 1984; Dutta et al., 1985) , and indeed all other transforming RNA tumor viruses, with the exception of the replicationcompetent strains of RSV, are replication-defective. The replication defect presumably reflects the substitution of retroviral sequences by host cell-derived (proto-oncogene) sequences. It also seems likely that the replicationcompetent strains arose from the replication-defective parent by recombination with the helper virus. The replication-competent strains of RSV proved to be particularly valuable for genetic studies of RSV, since, in the days before molecular cloning, these replicationcompetent viruses could be readily cloned by focus isolation. The discovery of these replication-competent strains therefore set the stage for genetic studies on RSV.
Transformation mutants
The first transformation mutants of RSV to be identified were the fusiform or morph f mutants of the Bryan strain of RSV, identified by Temin (1960) . These mutants induced the formation of spindle-shaped transformed cells, rather than the rounded cells resulting from infection by the wild-type (morph r ) virus. Temin concluded: 'Mutational differences in the virus determine the various morphologies of the infected cells, thus the virus becomes equivalent to a cellular gene controlling cell morphology'. (Temin was also impressed by the stable association between virus and cell that the properties of these mutants implied, and these and other observations led Temin to formulate the provirus hypothesis; a topic outside the scope of this review.) To digress briefly from our chronological account of the discovery of src: other mutants of this type were later isolated from the Prague and Schmidt-Ruppin strains (Parsons and Weber, 1989) . Many of these mutants also had an interesting and still poorly understood hostrange phenotype, transforming chicken embryo fibroblasts but not certain mammalian cell lines (or vice versa) (Varmus et al., 1981; DeClue and Martin, 1989) . This phenotype suggested that these mutations resulted in some alteration in the interaction of the Src protein The genome contains all of the genes necessary for viral replication (gag, pol, and env) plus the viral src gene. In the terminology of Duesberg and Vogt (1970) , these are a subunits. Cells singly infected by these viruses become transformed and release infectious progeny virus. (b) A replicationdefective mutant or a replication-defective strain such as the Bryan strain. The genome is defective in one or more of the genes required for virus replication; in the case of the Bryan strain, the env gene is deleted (and in some Bryan variants, pol also). Cells singly infected by these viruses become transformed but release either no virus, or, as in the case of the Bryan strain, noninfectious particles. Coinfection or superinfection by a helper virus, such as RAV (panel C), is required for the production of infectious viral progeny. (c) A nontransforming mutant of RSV. The genomes of these mutants are similar to those of an avian leukosis virus such as RAV or Rousinterfering factor (RIF), containing all the genes necessary for viral replication (gag, pol, and env), but not the viral src gene. In the terminology of Duesberg and Vogt (1970) , these are b subunits. Cells singly infected by these viruses release infectious progeny virus but do not become transformed with host cell targets. Molecular cloning and in vitro mutagenesis in the 1980s showed that these mutations lie within the SH2 and SH3 domains of Src (DeClue and Martin, 1989; Verderame et al., 1989) . These findings, and similar observations on a mutant of Fujinami sarcoma virus (DeClue et al., 1987) , provided one of the first clues that these domains mediate specific proteinprotein interactions.
Returning to the 60s and the road to src: the finding that transformation by the Bryan strain of RSV could occur without virus replication led to attempts to dissociate the two by irradiation of nondefective strains. Golde´and Latarjet (1966) irradiated Schmidt-Ruppin RSV with g-rays and found that this generated replication-defective mutants that yielded nonproducer pocks on the chorioallantoic membrane. Golde´and Toyoshima, Friis and Vogt then went on to show that g-ray or UV irradiation also generated nontransforming mutants that behaved much like the RAVs, replicating in chicken embryo fibroblasts without transforming them (Golde´, 1970; Toyoshima et al., 1970) (Figure 1 ). It was subsequently found that these nontransforming but replication-competent mutants of RSV arose spontaneously in unirradiated stocks (Vogt, 1971; Martin and Duesberg, 1972) . These nonconditional transformation-defective mutants of RSV proved to be key reagents for the physical identification of the viral src gene.
The most informative mutants were temperaturesensitive (ts) transformation-defective mutants. The use of ts mutants to dissect viral gene functions had been pioneered in the early 1960s by Bob Edgar at Caltech; he used a collection of ts mutants to identify the genes involved in the replication and assembly of bacteriophage T4 (Edgar and Lielausis, 1964) . Fried (1965) , also at Caltech in Dulbecco's laboratory, described the isolation of a ts mutant of polyoma virus defective both in the initiation of transformation and in viral replication. The isolation of this mutant did not reveal the identity of the polyoma virus transforming function; in retrospect, it seems that the complexity of polyoma viral gene expression and the presence of both replicative and transforming functions within the same gene conspired to delay the genetic dissection of the polyoma virus transforming function. Fried's studies did, however, provide an encouraging precedent for the use of ts mutants to study transformation by tumor viruses. Toyoshima and Vogt (1969) reported the identification of a ts mutant of B77 (a variant of the Prague strain of RSV), but this mutant failed to replicate at the nonpermissive temperature, and thus did not provide evidence for a specific transformation function. In 1970, working in the Rubin lab, I isolated a mutant of RSV that at the nonpermissive temperature failed to transform but continued to replicate, indicating that the defect was transformation-specific (Martin, 1970) . Moreover, when cells transformed by this mutant at the permissive temperature were then shifted to the nonpermissive temperature, they reverted to the normal phenotype, indicating that the mutant function was required for the maintenance of the transformed state. The gene identified by these ts mutants later proved to be identical to the gene deleted in the nonconditional mutants described above (Bernstein et al., 1976) . Thus, by 1970, the viral src gene had been identified, although this name was only bestowed on it a few years later.
The physical identification of viral src
Purification of RSV particles by density gradient centrifugation made it possible to determine its nucleic acid content, and Crawford (1960) showed that the virus contained an RNA genome. (At the time, this posed a problem for the idea that the virus was perpetuated as an integrated DNA analagous to the prophage of temperate bacteriophages. This conundrum was addressed by Temin's controversial proposal that reverse transcription could generate a DNA provirus; but again, this is another story.) In a series of studies from the Virus Laboratory at UC Berkeley, Bill Robinson and Peter Duesberg showed that the viral RNA was singlestranded and sedimented at 70S (Robinson et al., 1965 (Robinson et al., , 1967 . Duesberg then showed that the 70S RNA could be dissociated into two smaller 35S subunits by heat or DMSO treatment (Duesberg, 1968) . After the discovery of nondefective strains of RSV and the isolation of transformation-defective mutants, it became possible to ask whether the genome of nondefective strains of RSV differed from the genome of a transformation-defective mutant or that of a replication-competent but nontransforming virus such as a RAV. To approach this question, Duesberg and Vogt carried out co-electrophoresis of viral RNAs labeled with [ (Duesberg and Vogt, 1970) ; the presence of the smaller b subunits in the RSV stocks later proved to be due to the presence of spontaneous nontransforming segregants in these stocks (Vogt, 1971; Martin and Duesberg, 1972) . These findings led Duesberg and Vogt to propose that there might be a sequence within the a subunit that was lacking in the b subunit and that was responsible for transformation of fibroblasts: in other words, a ¼ b þ x, where x is the transforming gene of the virus (Figure 1) .
To further characterize the transforming gene, Duesberg and his colleagues turned to oligonucleotide fingerprinting, a technique invented by Fred Sanger at the Medical Research Council Laboratory of Molecular Biology in England. In this technique, RNAs are subjected to endonucleolytic cleavage by the ribonuclease T1 and the resulting oligonucleotides separated in two dimensions. Sure enough, the RNAs of nondefective RSVs contained several oligonucleotides absent from transformation-defective mutants derived from them. To determine if these oligonucleotides were present in a single contiguous segment, Duesberg and his group then made use of the fact that RSV viral RNA is polyadenylated, that is, it contains a 3 0 polyA tract that binds to oligo-dT; chromatography on oligo-dT and sucrose gradient centrifugation were used to fractionate partially cleaved viral RNA into segments of increasing length extending from the 3 0 terminus. The oligonucleotides unique to transformation-competent RSV proved to reside close to the 3 0 terminus. Thus, the sequence responsible for transformation appeared to correspond to a single contiguous segment, most likely a single gene (Wang et al., 1976) .
The v-Src protein
In these days of molecular cloning and in vitro gene expression, it is hard to remember the challenges faced by investigators in the early 1970s who were trying to identify the product of the newly discovered viral src gene. These difficulties were compounded by a lack of understanding of how retroviral genes are expressed. The discovery of reverse transcriptase by Howard Temin (Temin and Mizutani, 1970) and David Baltimore (Baltimore, 1970) had led to acceptance of the previously heretical idea that the genome is reverse transcribed into a DNA copy that becomes integrated as a provirus. However, the mechanism by which a viral gene at the 3' end of the genome could be expressed was not understood. It was only in 1977 that the identification of a subgenomic message containing src sequences was reported (Weiss et al., 1977) , following the discovery of splicing earlier that year. Despite these uncertainties, several groups attempted to identify the src gene product by in vitro translation of viral RNAs. Karen Beemon, a postdoc in Tony Hunter's lab, and Jim Kamine in John Buchanan's lab, identified polypeptide translation products that were src specific (Beemon and Hunter, 1977; Kamine and Buchanan, 1977) , but these were quite small (18 and 25 kDa), and in retrospect probably resulted from internal initiation and/or premature termination.
An alternative approach was to define the src gene product as a tumor antigen. The precedent here was the pioneering studies of Bob Huebner and his colleagues at the NIH, who had detected the early gene product of SV40 as a tumor or T antigen (Black et al., 1963) . The fact that some strains of RSV could induce tumors in mammals led a number of groups to search for an RSV-induced tumor antigen. But early attempts failed, perhaps because the close similarity between the v-Src and c-Src proteins makes the generation of anti-Src antibodies more difficult than the generation of antibodies against papovavirus T antigens, which have no close cellular homolog. Joan Brugge and Ray Erikson achieved success by using antisera from rabbits injected as newborns with Schmidt-Ruppin RSV and bearing RSV-induced tumors. In 1977, they reported that they had been able to immunoprecipate a 60 kDa phosphoprotein from cells transformed by RSV using the sera from tumor-bearing rabbits (TBR sera) (Brugge and Erikson, 1977) . This 60 kDa phosphoprotein proved to be the long-sought src gene product.
A (Collett and Erikson, 1978; Levinson et al., 1978) . For some time, there was a controversy as to whether this activity was intrinsic to Src or merely associated with it. This controversy was finally laid to rest when both v-Src and the catalytic chain of the cyclic AMPdependent protein kinase had been cloned and sequenced (Czernilofsky et al., 1980 (Czernilofsky et al., , 1983 Shoji et al., 1981; Takeya and Hanafusa, 1982; Schwartz et al., 1983) and were found to be to be homologous (Barker and Dayhoff, 1982) .
The Src kinase activity was initially described as threonine-specific. But, in 1979, Tony Hunter and his colleagues at the Salk Institute discovered a novel phosphoamino acid, phosphotyrosine, present in polyoma middle T antigen (Eckhart et al., 1979) . This discovery was quite serendipitous. Hunter's and other groups, impressed by the discovery of the v-Src kinase activity, were examining the possibility that polyoma virus T antigens might have an intrinsic or associated kinase activity, and had discovered that polyoma virus middle T became phosphorylated in immune complex kinase assays. In analysing the phosphoaminoacids released by partial acid hydrolysis of polyoma virus middle T phosphorylated in vitro, Hunter used an old batch of pH 1.9 electrophoresis buffer; it so happens that phosphothreonine and phosphotyrosine do not separate on electrophoresis at pH 1.9 in acetic acid/ formic acid/water buffer, but do separate at the lower pH of 'aged' buffer, from which the more volatile acetic acid has escaped (T Hunter, personal communication; Ushiro and Cohen, 1980) . Also serendipitously, Hunter happened to use as a control immunoglobulin heavy chain phosphorylated by Src in an immune complex kinase assay, and discovered that this too was phosphorylated at tyrosine. This suggested that Src might itself be a tyrosine kinase. The following year, he and Bart Sefton reported that Src phosphorylated exogenous substrates and cellular proteins at tyrosine and that it was itself phosphorylated at tyrosine (Hunter and Sefton, 1980) . In the same year, David Baltimore's laboratory independently discovered that the Abelson murine leukemia virus v-Abl protein also underwent phosphorylation at tyrosine (Witte et al., 1980) . Stan Cohen's laboratory made similar observations on the epidermal growth factor receptor (Ushiro and Cohen, 1980) . These findings set off a frenzied hunt for cellular substrates of Src and other tyrosine kinases, which I have described elsewhere (Martin, 2001 ).
The c-src proto-oncogene
In 1969, Huebner and Todaro proposed the 'oncogene' hypothesis of cancer. This hypothesis was based on the discovery that RNA tumor viruses could be transmitted genetically. They postulated that some of these endogenous viruses contained transforming genes or 'oncogenes,' and that activation of these endogenous transforming viruses could cause cancer (Huebner and Todaro, 1969) .
The discovery that RSV contained a defined gene required for transformation opened up a new way of looking for genes that might be involved in cancer. Mike Bishop and Harold Varmus at UC San Francisco began thinking about the origin of the viral src gene. Impressed by the finding that this gene was dispensable for virus replication (Golde´, 1970; Martin, 1970; Toyoshima et al., 1970) , they speculated that it might be of cellular origin. In other words, rather than viruses having inserted transforming genes into the genome, as Huebner and Todaro had proposed, transforming viruses might have captured cellular genes. To examine this idea, Dominique Stehelin, working in the Bishop-Varmus laboratory, prepared a cDNA probe specific for src by reverse transcription of RSV RNA, followed by hybridization to the RNA of a nontransforming mutant and hydroxyapatite chromatography (Stehelin et al., 1976a) . Working with Peter Vogt, they then hybridized this src-specific probe to normal avian DNAs and discovered that the probe did indeed hybridize to a variety of avian DNAs, including DNAs of primitive ratite birds such as the emu and the rhea (Stehelin et al., 1976b) . The finding that the sequences detected in this way were conserved in evolution provided evidence that they were of cellular rather than viral origin, since endogenous retroviruses are generally species-specific. The cellular nature of these sequences was confirmed when the cellular src gene was cloned and was found to be unlinked to viral sequences and to have the typical exon/intron structure of a normal cellular gene (Shalloway et al., 1981; Takeya and Hanafusa, 1983) . The term proto-oncogene was coined to describe the new type of gene, to distinguish these genes from the oncogenes postulated by Huebner and Todaro, and to emphasize that, although representing the precursors of viral transforming genes, they are not themselves transforming unless mutated and/or overexpressed (Iba et al., 1984; Parker et al., 1984; Shalloway et al., 1984) .
Coda and further reading
The discovery of c-src set off an explosion of research into the role of proto-oncogenes in cancer, and in 1989 the discovery earned Bishop and Varmus the Nobel Prize in Physiology or Medicine. The last two decades of the 20th century also saw an intensive effort to understand the structure and function of the Src protein.
These years saw the discovery of the Src homology domains and the development of the concept of modular protein interaction domains (Sadowski et al., 1986; Mayer et al., 1988; Pawson, 2004) ; the solution of the structure of Src and an understanding of its mode of regulation (Sicheri et al., 1997; Xu et al., 1997 Xu et al., , 1999 ; the identification of Src family members and the generation of knockout mice lacking one or more Src family kinases (Soriano et al., 1991; Stein et al., 1994; Lowell and Soriano, 1996) ; the identification of Src substrates, Srcregulated signaling pathways, and cellular functions regulated by Src family kinases (Thomas and Brugge, 1997) ; and the finding that Src activity is elevated in many human epithelial cancers (Jacobs and Rubsamen, 1983; Bolen et al., 1987; Frame, 2002; Yeatman, 2004) . I have described much of this later research on Src, as well as the earlier studies described here, in another review (Martin, 2001) . For an account of the discovery of Rous sarcoma virus, see Oncogenic Viruses (Gross, 1983) and An Introduction to the History of Virology (Waterson and Wilkinson, 1978) . The development of the plaque and focus assays is reviewed in chapters by Renato Dulbecco and Harry Rubin in Phage and the Origins of Molecular Biology (Cairns et al., 1992) . For a history of retrovirology, see Peter Vogt's chapter (Chapter 1) in Retroviruses (Coffin et al., 1997) . Mike Bishop's memoir, How to Win a Nobel Prize (Bishop, 2003) , contains an engrossing account of the history of cancer research and the discovery of cellular src.
